26.6.2025 14:33:26 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, Norway, 26 June 2025: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 18 June 2025 regarding the
successful completion of a private placement of new shares (the "Private
Placement") raising gross proceeds of approximately NOK 75 million and a retail
offering of new shares (the "PrimaryBid Offering") raising gross proceeds of
approximately NOK 11.4 million, and the disclosure of large shareholding
notification on 18 June 2025 regrading, inter alia, the effectuation of a share
loan under a share lending agreement entered into by and between the Company,
its shareholder Scatec Innovation AS as share lender and Arctic Securities AS
and DNB Carnegie, a part of DNB Bank ASA, as managers (the "Managers"), to
facilitate delivery-versus-payment settlement in the Privat Placement and the
PrimaryBid Offering (the "Share Lending Agreement").

Today, following registration of the share capital increases pertaining to the
Private Placement and the PrimaryBid Offering, the Managers will redeliver
31,577,399 new shares in the Company to Scatec Innovation AS pursuant to the
Share Lending Agreement. Following the effectuation of the redelivery of
31,577,399 new shares in the Company and the delivery of 3,000,000 new shares
allocated to Scatec Innovation AS in the Private Placement, Scatec Innovation
AS' holding of shares in the Company will be 81,419,309, equivalent to approx.
23.3% of the issued share capital and votes. Consequently, Scatec Innovation AS
will cross above the 15% and 20% thresholds pursuant to section 4-2 (1) and (3)
of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV
AS, which holds 354,453 shares in the Company. Scatec Innovation AS aggregated
holding of shares is thus 81,773,762, equivalent to approx. 23.4% of the shares
and votes in the Company.

Scatec Innovation AS is a close associate of chairman John Andersen. Primary
insider notification pursuant to the market abuse regulation article 19 is
attached.

This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act and is subject to disclosure requirements pursuant to the
EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading
Act section and 5-12.

Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.com - http://www.thormedical.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581841/6255/Download%20announce
ment%20as%20PDF.pdf

20250626 - Primary insider notifications Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581841/6254/20250626%20-%20Prim
ary%20insider%20notifications%20Scatec%20Innovation%20AS.pdf